A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03395704 |
Recruitment Status :
Completed
First Posted : January 10, 2018
Last Update Posted : March 4, 2020
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hereditary Hemochromatosis | Drug: LJPC-401 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 69 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis |
Actual Study Start Date : | November 29, 2017 |
Actual Primary Completion Date : | October 28, 2019 |
Actual Study Completion Date : | October 28, 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: LJPC-401
LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
|
Drug: LJPC-401
LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
Other Name: synthetic human hepcidin |
Placebo Comparator: Placebo
0.9% Sodium Chloride Injection, USP, or equivalent
|
Drug: Placebo
0.9% Sodium Chloride Injection, USP, or equivalent
Other Name: Normal saline |
- Effect of LJPC-401 versus placebo on blood iron levels [ Time Frame: 16 Weeks ]Change in transferrin saturation (TSAT) as measured by blood laboratory tests.
- Effect of LJPC-401 versus placebo on incidence of phlebotomy [ Time Frame: 16 Weeks ]
- Effect of LJPC-401 versus placebo on blood iron levels [ Time Frame: 16 Weeks ]Change in serum ferritin as measured by blood laboratory tests
- Effect of LJPC-401 versus placebo on the incidence of treatment-emergent adverse events [ Time Frame: 20 Weeks ]
- Effect of LJPC-401 versus placebo on clinical chemistry laboratory parameters [ Time Frame: 20 Weeks ]Safety measure for clinical chemistry parameters including serum creatinine, uric acid, alkaline phosphatase, blood urea nitrogen, albumin, bilirubin (total), phosphate, bicarbonate, lactate dehydrogenase, glucose, calcium, magnesium, chloride, sodium, potassium, alanine aminotransferase, aspartate aminotransferase, and total protein will be assessed. In addition, serum pregnancy test will be assessed.
- Effect of LJPC-401 versus placebo on hematology laboratory parameters [ Time Frame: 20 Weeks ]Safety measure for laboratory hematology parameters including platelet count, red blood cell count, absolute white blood cell count, hemoglobin, hematocrit, reticulocyte count, red cell distribution width, mean corpuscular hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin concentration will be assessed.
- Effect of LJPC-401 versus placebo on blood iron parameters [ Time Frame: 20 Weeks ]Exploratory measure of serum iron, serum transferrin, total iron-binding capacity, unsaturation iron-binding capacity will be assessed to evaluate iron parameters.
- Effect of LJPC-401 versus placebo on endocrine laboratory parameters [ Time Frame: 16 Weeks ]Exploratory measure for endocrine laboratory parameters, including thyroid-stimulating hormone, thyroxine (T4), and triiodothyronine (T3) will be assessed to evaluate changes in thyroid function.
- Effect of LJPC-401 versus placebo on glucose levels [ Time Frame: 16 Weeks ]Exploratory measure for change in hemoglobin A1c will be assessed to evaluate blood sugar levels.
- Effect of LJPC-401 versus placebo on urinalysis laboratory parameters [ Time Frame: 20 Weeks ]Safety measure for urinalysis laboratory parameters including specific gravity, bilirubin, glucose, pH, protein, nitrite, blood, ketones will be assessed. In addition, urine pregnancy test will be assessed at Week 1 (Day 1) to reconfirm eligibility predose and at again at Week 20 for additional safety assessment.
- Effect of LJPC-401 versus placebo on blood pressure [ Time Frame: 20 Weeks ]Safety measure for change in blood pressure.
- Effect of LJPC-401 versus placebo on heart rate [ Time Frame: 20 Weeks ]Safety measure for change in heart rate (bpm).
- Effect of LJPC-401 versus placebo on body weight [ Time Frame: 20 Weeks ]Safety measure for change in body weight (kilograms).
- Effect of LJPC-401 versus placebo on body temperature [ Time Frame: 20 Weeks ]Safety measure for change in body temperature (Celsius).
- Effect of LJPC-401 versus placebo on general health [ Time Frame: 20 Weeks ]Safety measure for change in physical examination (by body system).
- Effect of LJPC-401 versus placebo on electrical activity of the heart [ Time Frame: 20 Weeks ]Safety measure for change in the electrical activity of the heart over a period of time using electrodes placed on the skin and recorded by electrocardiogram (ECG).
- Effect of LJPC-401 versus placebo on its potential to elicit an immune response [ Time Frame: 20 Weeks ]Safety measure of blood samples collected to assess the presence of anti-drug antibodies.
- Effect of LJPC-401 versus placebo on quality of life [ Time Frame: 16 Weeks ]Exploratory measure for change in quality of life as measured by the Short Form Health Survey version 2.0 questionnaire. The scale measures physical functioning; role-physical, bodily pain; general health; vitality; social functioning; role-emotional; mental health and reported health transition. The responses vary depending on the question: Range 1-6 (none to very severe); range 1-5 (all of the time to none of the time or definitely true to definitely false); range 1-4 not at all to quite a bit; range 1-3 (yes, limited a lot to no, not limited at all). All scoring will be tallied by a validated central system (Optum) and provided to the sponsor at the end of the study. Scoring will be analyzed as a change from baseline to end of treatment (Week 16).
- Effect of LJPC-401 versus placebo on quality of life [ Time Frame: 16 Weeks ]Exploratory measure for change in quality of life as measured by the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire. The scale ranges from 1-5 (none to extreme in regards to pain and difficulty during day to day activity. Responses will be analyzed as a change from baseline to end of treatment (Week 16).
- Exploratory measure for change in quality of life [ Time Frame: 16 Weeks ]Exploratory measure for change in quality of life as measured by the Modified Dreisler indicies (FIOHA-Functional Index for Hand OsteoArthritis) questionnaire. The scale ranges from 1-4 (Possible without difficulty to impossible in regards to activities that use hand movement. The results are totaled and scores will be analyzed as a change from baseline to end of treatment (Week 16).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with clinical diagnosis of hereditary hemochromatosis
- Patients who are prescribed therapeutic phlebotomy for treatment of hereditary hemochromatosis
- Patients with serum ferritin and TSAT levels above treatment guidelines
- Female patients of child bearing potential must have a negative pregnancy test and must be using a highly effective method of contraception during participation in the study, and for 30 days after the last dose of study drug
- Males must be surgically sterile (vasectomy), or using a highly effective method of contraception during participation in the study, and for 30 days after the last dose of study drug
- Patient must be willing and able to provide written informed consent
Exclusion Criteria:
- Patients receiving iron chelation therapy within 7 days prior to the first dose of study drug
- Patients initiating phlebotomy treatments less than 3 months prior to the first dose of study drug
- Pregnant or lactating women
- Patients taking an immunosuppressive agent without prior Sponsor approval
- Patients participating in an unapproved investigational drug or investigational therapeutic device within 30 days of study drug
- Patients who are unwilling or unable to comply with the study protocol requirements
- Patients with type 1 or poorly controlled type 2 diabetes
- Patients with a concomitant disease, disability or condition, including laboratory abnormality and ECG findings, which may interfere with the conduct of the study, or which would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study, including, but not limited to, clinically significant arrhythmias, alcohol dependency or abuse, drug dependency or abuse, or psychiatric disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395704
United States, Arkansas | |
Investigative Site | |
North Little Rock, Arkansas, United States, 72117 | |
United States, California | |
Investigative Site | |
Los Angeles, California, United States, 90036 | |
Investigative Site | |
Palo Alto, California, United States, 94305 | |
Investigative Site | |
Rialto, California, United States, 92377 | |
Investigational Site | |
San Diego, California, United States, 91942 | |
Investigative Site | |
San Francisco, California, United States, 94115 | |
United States, Florida | |
Investigative Site | |
Jacksonville, Florida, United States, 32204 | |
United States, Indiana | |
Investigative Site | |
Indianapolis, Indiana, United States, 46202 | |
United States, Michigan | |
Investigative Site | |
Wyoming, Michigan, United States, 49519 | |
United States, Mississippi | |
Investigative Site | |
Jackson, Mississippi, United States, 39216 | |
United States, New York | |
Investigative Site | |
East Setauket, New York, United States, 11733 | |
Investigative Site | |
Manhasset, New York, United States, 11030 | |
Investigative Site | |
New York, New York, United States, 10029 | |
United States, Texas | |
Investigative Site | |
Dallas, Texas, United States, 75246 | |
Investigative Site | |
Fort Worth, Texas, United States, 76104 | |
Investigative Site | |
Houston, Texas, United States, 77058 | |
Investigative Site | |
San Antonio, Texas, United States, 78215 | |
United States, Washington | |
Investigative Site | |
Seattle, Washington, United States, 98104 | |
Australia, New South Wales | |
Investigative Site | |
Liverpool, New South Wales, Australia, 2170 | |
Investigative Site | |
Westmead, New South Wales, Australia, 2145 | |
Australia, Queensland | |
Investigative Site | |
Brisbane, Queensland, Australia, 4120 | |
Investigative Site | |
Herston, Queensland, Australia, 4029 | |
Australia, Victoria | |
Investigative Site | |
Melbourne, Victoria, Australia, 3004 | |
Australia, Western Australia | |
Investigative Site | |
Murdoch, Western Australia, Australia, 6150 | |
France | |
Investigative Site | |
Bondy, France, 93140 | |
Investigative Site | |
Orléans, France, 45000 | |
Investigative Site | |
Pessac, France, 33604 | |
Investigative Site | |
Rennes Cedex 9, France, 35033 | |
United Kingdom | |
Investigative Site | |
Bradford, England, United Kingdom, BD9 6RJ | |
Investigative Site | |
Newcastle Upon Tyne, England, United Kingdom, NE7 7DN | |
Investigative Site | |
Portsmouth, England, United Kingdom, PO6 3LY |
Responsible Party: | La Jolla Pharmaceutical Company |
ClinicalTrials.gov Identifier: | NCT03395704 |
Other Study ID Numbers: |
LJ401-HH01 |
First Posted: | January 10, 2018 Key Record Dates |
Last Update Posted: | March 4, 2020 |
Last Verified: | March 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hemochromatosis Iron Overload Iron Metabolism Disorders Metabolic Diseases Metal Metabolism, Inborn Errors |
Metabolism, Inborn Errors Genetic Diseases, Inborn Hepcidins Anti-Infective Agents |